Bladé J - Search Results

1

Cibeira MT, Ortiz-Pérez JT, Quintana LF, Fernádez de Larrea C, Tovar N, Bladé J. Cibeira MT, et al. Among authors: blade j. Acta Haematol. 2020;143(4):335-342. doi: 10.1159/000506760. Epub 2020 Apr 1. Acta Haematol. 2020. PMID: 32235118 Review.

2

Response to thalidomide in multiple myeloma: impact of angiogenic factors.

Rosiñol L, Cibeira MT, Segarra M, Cid MC, Filella X, Aymerich M, Rozman M, Arenillas L, Esteve J, Bladé J, Montserrat E. Rosiñol L, et al. Among authors: blade j. Cytokine. 2004 May 21;26(4):145-8. doi: 10.1016/j.cyto.2004.02.002. Cytokine. 2004. PMID: 15149630

3

Extramedullary multiple myeloma escapes the effect of thalidomide.

Rosiñol L, Cibeira MT, Bladé J, Esteve J, Aymerich M, Rozman M, Segarra M, Cid MC, Filella X, Montserrat E. Rosiñol L, et al. Among authors: blade j. Haematologica. 2004 Jul;89(7):832-6. Haematologica. 2004. PMID: 15257935

4

Bortezomib-induced severe hepatitis in multiple myeloma: a case report.

Rosiñol L, Montoto S, Cibeira MT, Bladé J. Rosiñol L, et al. Among authors: blade j. Arch Intern Med. 2005 Feb 28;165(4):464-5. doi: 10.1001/archinte.165.4.464. Arch Intern Med. 2005. PMID: 15738379

5

Comparative genomic hybridisation identifies two variants of smoldering multiple myeloma.

Rosiñol L, Carrió A, Bladé J, Queralt R, Aymerich M, Cibeira MT, Esteve J, Rozman M, Campo E, Montserrat E. Rosiñol L, et al. Among authors: blade j. Br J Haematol. 2005 Sep;130(5):729-32. doi: 10.1111/j.1365-2141.2005.05673.x. Br J Haematol. 2005. PMID: 16115129 Free article.

6

Bortezomib: a valuable new antineoplastic strategy in multiple myeloma.

Bladé J, Cibeira MT, Rosiñol L. Bladé J, et al. Acta Oncol. 2005;44(5):440-8. doi: 10.1080/02841860510030002. Acta Oncol. 2005. PMID: 16118077 Review.

7

Development of rapidly progressive liver light chain deposition under VAD chemotherapy in multiple myeloma.

Samanez C, Domingo A, Cibeira MT, Miquel R, Soler M, Bladé J. Samanez C, et al. Among authors: blade j. Eur J Haematol. 2006 Jan;76(1):83-5. doi: 10.1111/j.1600-0609.2005.00561.x. Eur J Haematol. 2006. PMID: 16343276

8

Bortezomib: an effective agent in extramedullary disease in multiple myeloma.

Laura R, Cibeira MT, Uriburu C, Yantorno S, Salamero O, Bladé J, Montserrat E. Laura R, et al. Among authors: blade j. Eur J Haematol. 2006 May;76(5):405-8. doi: 10.1111/j.0902-4441.2005.t01-1-EJH2462.x. Epub 2006 Mar 9. Eur J Haematol. 2006. PMID: 16529604

9

Long-term results of thalidomide in refractory and relapsed multiple myeloma with emphasis on response duration.

Cibeira MT, Rosiñol L, Ramiro L, Esteve J, Torrebadell M, Bladé J. Cibeira MT, et al. Among authors: blade j. Eur J Haematol. 2006 Dec;77(6):486-92. doi: 10.1111/j.0902-4441.2006.t01-1-EJH2783.x. Epub 2006 Sep 15. Eur J Haematol. 2006. PMID: 16978238

10

Bortezomib-induced rhabdomyolysis in multiple myeloma.

Cibeira MT, Mercadal S, Arenillas L, Muntañola A, Salamero O, Bladé J. Cibeira MT, et al. Among authors: blade j. Acta Haematol. 2006;116(3):203-6. doi: 10.1159/000094682. Acta Haematol. 2006. PMID: 17016040

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

555 results

Search Page

Filters